Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue
+1.44%
EPS
−21.6%
Free cash flow
−25.3%
Total debt
+3.04%

Quarter to September 2026, against a year earlier

42.83 1.81 −4.05%
Market cap
$64.7B
P/E
18.7×
Fwd P/E
17.0×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a

Boston Scientific Corporation 10-Q filed May 1, 2025

Fiscal Q1 2025 · Period ended Mar 31, 2025 · Filed · accepted 6:31 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 1, 2024: no comparison — the earlier filing's text is no longer kept